Communiqués Monopar Therapeutics Inc.

Actions

MNPR

US61023L2079

Recherche biotechnologique et médicale

Marché Fermé - Nasdaq 22:00:00 09/10/2026			Varia. 5j.	Varia. 1 janv.
78,96 ^USD	-5,98 %		+1,27 %	+20,92 %

05/10	Un initié de Monopar Therapeutics a vendu des actions pour 659 387 dollars, selon un récent dépôt auprès de la Securities and Exchange Commission (SEC)	MT
19/08	Monopar Therapeutics Inc. annonce la nomination de Jeffrey D. Kent au poste de vice-président exécutif, responsable des affaires médicales, à compter du 1er septembre 2026	CI

Communiqués

20/08	Monopar Appoints Jeffrey D. Kent, M.D., as Executive Vice President, Head of Medical Affairs; Announces Two ALXN1840 Presentations at AASLD - the Liver Meeting(R) 2026	AQ
19/08	Monopar Appoints Jeffrey D. Kent, M.D., as Executive Vice President, Head of Medical Affairs; Announces Two ALXN1840 Presentations at AASLD – The Liver Meeting® 2026	AQ
13/08	Monopar Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Updates	AQ
12/08	Monopar Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Updates	AQ
22/07	Monopar Initiates Rolling NDA Submission for ALXN1840 in Wilson Disease	AQ
20/07	Monopar Advances Launch Readiness with Addition of Veteran Commercial Executive Nicole Sweeny to Board of Directors and Expansion of Commercial Leadership Team	AQ
30/06	Monopar Therapeutics Receives FDA Rare Pediatric Disease Designation for ALXN1840 for the Treatment of Wilson Disease	AQ
26/06	Monopar Presents New Analyses of Phase 3 FoCus Data at EAN 2026 Showing Greater Neurologic and Global Clinical Benefit with ALXN1840 Versus Standard of Care in Wilson Disease	AQ
01/06	Monopar Presents Phase 2 ALXN1840 Data Demonstrating Liver Disease Stabilization and Neurologic Improvement in Treatment-Experienced Wilson Disease Patients at EASL 2026	AQ
19/05	Monopar Announces Publication of Phase 2 Study Demonstrating ALXN1840 Significantly Improves Copper Balance in Patients with Wilson Disease	AQ
14/05	Monopar Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Updates	AQ
20/04	Monopar Presents Phase 3 Data Showing Greater Neurologic Benefit with ALXN1840 vs SoC in Wilson Disease Patients with Neurologic Symptoms at AAN 2026	AQ
30/03	Monopar Reports Fourth Quarter and Full-Year 2025 Financial Results and Provides Business Update	AQ
27/03	Monopar Reports Fourth Quarter and Full-Year 2025 Financial Results and Provides Business Update	AQ
02/03	Monopar Expands Leadership Team with Appointment of Seasoned Biopharma Executive Susan Rodriguez as Chief Commercial and Strategy Officer	AQ
13/11	Monopar Therapeutics Reports Third Quarter 2025 Financial Results and Recent Developments	AQ
09/11	Monopar Presents New Data and Analyses on Rapidly Improved Copper Balance in Wilson Disease Patients on Tiomolybdate Choline at AASLD - The Liver Meeting® 2025	AQ
15/10/25	Monopar Announces Abstract Accepted for Oral Presentation at AASLD - The Liver Meeting® 2025	AQ
24/09/25	Monopar Therapeutics Inc. Announces Pricing of $135 Million Underwritten Offering of Common Stock and Pre-Funded Warrants	AQ
24/09/25	Monopar Announces Journal of Hepatology Publishes Physicians’ Letter to the Editor Demonstrating ALXN1840 Rapidly Improved Copper Balance in Wilson Disease Patients	AQ
14/09/25	Monopar to Present New Long-Term Neurological Efficacy and Safety Data for ALXN1840 in Wilson Disease at the 150th American Neurological Association Annual Meeting	AQ
03/09/25	Monopar Announces Abstract Accepted with Distinction for Oral and Poster Presentations at the Upcoming American Neurological Association 2025 Annual Meeting	AQ
12/08/25	Monopar Therapeutics Reports Second Quarter 2025 Financial Results and Recent Developments	AQ
11/06/25	Monopar and EDNOC Announce Expanded Access Program for MNPR-101-Zr and MNPR-101-Lu in Advanced Cancers	AQ
03/06/25	Monopar Therapeutics Announces Inclusion in the Russell 3000® and Russell 2000® Indexes	AQ